Harbor Capital Advisors Inc. Acquires 174 Shares of Gilead Sciences, Inc. $GILD

Harbor Capital Advisors Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 622 shares of the biopharmaceutical company’s stock after acquiring an additional 174 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Gilead Sciences were worth $69,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the period. Nuveen LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. GAMMA Investing LLC increased its stake in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after purchasing an additional 2,532,070 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after buying an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after acquiring an additional 1,942,433 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD opened at $114.09 on Friday. Gilead Sciences, Inc. has a 12-month low of $81.83 and a 12-month high of $121.83. The firm has a market capitalization of $141.56 billion, a P/E ratio of 22.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. The stock’s 50 day moving average price is $114.10 and its two-hundred day moving average price is $110.03. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the sale, the chief financial officer directly owned 160,110 shares in the company, valued at $18,977,838.30. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock worth $9,390,030 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, UBS Group lifted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.